Agnico Eagle Mines Limited (AEM)
NYSE: AEM · Real-Time Price · USD
135.61
-0.17 (-0.13%)
At close: Aug 8, 2025, 4:00 PM
136.49
+0.88 (0.65%)
After-hours: Aug 8, 2025, 7:59 PM EDT
Checkpoint Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Checkpoint Therapeutics stock have a consensus rating of "Buy" and an average price target of $124.63, which forecasts a -8.10% decrease in the stock price over the next year. The lowest target is $85 and the highest is $173.
Price Target: $124.63 (-8.10%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Checkpoint Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 5 | 5 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| CIBC | CIBC | Buy Maintains $134 → $165 | Buy | Maintains | $134 → $165 | +21.67% | Jul 15, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $170 → $173 | Strong Buy | Maintains | $170 → $173 | +27.57% | Jun 23, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $105 → $126 | Buy | Maintains | $105 → $126 | -7.09% | Apr 14, 2025 |
| UBS | UBS | Hold Maintains $110 → $115 | Hold | Maintains | $110 → $115 | -15.20% | Apr 11, 2025 |
| Raymond James | Raymond James | Buy Maintains $105 → $130 | Buy | Maintains | $105 → $130 | -4.14% | Apr 4, 2025 |
Financial Forecast
Revenue This Year
10.64B
from 8.29B
Increased by 28.39%
Revenue Next Year
10.84B
from 10.64B
Increased by 1.92%
EPS This Year
5.30
from 3.78
Increased by 40.25%
EPS Next Year
5.29
from 5.30
Decreased by -0.23%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.7B | 12.6B | 10.3B | ||
| Avg | 10.6B | 10.8B | 8.5B | ||
| Low | 9.7B | 9.1B | 6.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.9% | 18.8% | -5.0% | ||
| Avg | 28.4% | 1.9% | -21.4% | ||
| Low | 17.2% | -14.3% | -36.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.76 | 6.76 | 5.13 | ||
| Avg | 5.30 | 5.29 | 4.11 | ||
| Low | 3.55 | 3.68 | 3.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 78.9% | 27.5% | -2.9% | ||
| Avg | 40.3% | -0.2% | -22.2% | ||
| Low | -6.1% | -30.5% | -40.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.